Share on LinkedInShare on LinkedIn

ARTICLE · 25 MARCH 2011

Specification Limits The Invention Even In The Absence Of Explicit Claim Language

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

In Hologic, Inc. v. SenoRx, Inc., No. 10-1235 (Fed. Cir. Feb. 24, 2011), the Federal Circuit reversed the district court’s SJ finding of invalidity because it was based on an erroneous claim construction.

United StatesIntellectual Property

Last Month at the Federal Circuit - March 2011

Judges: Newman, Friedman (dubitante), Lourie (author)
[Appealed from N.D. Cal., Senior Judge Whyte]

In Hologic, Inc. v. SenoRx, Inc., No. 10-1235 (Fed. Cir. Feb. 24, 2011), the Federal Circuit reversed the district court's SJ finding of invalidity because it was based on an erroneous claim construction.

Hologic, Inc. ("Hologic") owns U.S. Patent No. 6,482,142 ("the '142 patent"), which discloses a balloon brachytherapy device with a means for providing a predetermined asymmetric isodose profile within a target tissue. Balloon brachytherapy is a type of radiation therapy in which a balloon is inserted into the body at or near a tumor or other proliferative tissue disease site. Hologic brought suit against SenoRx, Inc. ("SenoRx") alleging that SenoRx's balloon brachytherapy device infringed its patents. SenoRx conceded infringement of claims 1 and 8 of the '142 patent but argued that the asserted claims were

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from